How long should treatment with bevacizumab for degenerative maculopathy be monitored before determining it is ineffective, and what clinical symptoms should be assessed?
Fuente:
Zenodo
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Recurso digital |
| Pubblicazione: |
Zenodo
2026
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866902228235714560 |
|---|---|
| author | Tripdatabase |
| author_facet | Tripdatabase |
| contents | Monitoring bevacizumab treatment in degenerative maculopathy should continue for at least 3-12 months to assess effectiveness, focusing on visual acuity and retinal imaging results. |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_20398190 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | How long should treatment with bevacizumab for degenerative maculopathy be monitored before determining it is ineffective, and what clinical symptoms should be assessed? Tripdatabase degenerative maculopathy bevacizumab treatment efficacy clinical symptoms ophthalmology Monitoring bevacizumab treatment in degenerative maculopathy should continue for at least 3-12 months to assess effectiveness, focusing on visual acuity and retinal imaging results. |
| title | How long should treatment with bevacizumab for degenerative maculopathy be monitored before determining it is ineffective, and what clinical symptoms should be assessed? |
| topic | degenerative maculopathy bevacizumab treatment efficacy clinical symptoms ophthalmology |
| url | https://doi.org/10.5281/zenodo.20398190 |